Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the...

Innate will no longer pursue Lumoxiti commercialization activities in US or EU; Company to re-focus investments in its R&D portfolio Companies will develop a transition plan with the goal of returning...

Phase 2 expansion cohort data supports ongoing Phase 3 trial Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that it will...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today released its 2021 financial calendar: March 18, 2021: Publication of 2020 financial...

Lacutamab granted PRIME designation in Sézary Syndrome by the European Medicines Agency Monalizumab Phase 3 study initiated, triggering $50 million milestone payment Cash position of €163.6 million*...

Priority Medicines (PRIME) designation supports the potential for lacutamab to benefit Sézary Syndrome patients in need of new treatment options Innate Pharma SA (Euronext Paris: IPH – ISIN...

Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that members of its senior management team are scheduled to participate in...

Milestone payment further bolsters Innate’s cash position INTERLINK-1 represents first Phase 3 study examining IO approach in R/M SCCHN patients who have been treated with a platinum-based therapy and...